




## Tenapanor

Revised: November 15, 2023.

CASRN: 1234423-95-0



## Drug Levels and Effects

### Summary of Use during Lactation

Tenapanor is essentially non-absorbed systemically, with undetectable plasma concentrations following oral administration. The minimal systemic absorption of tenapanor will not result in a clinically relevant exposure to breastfed infants. No special precautions are necessary.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Tenapanor

### CAS Registry Number

1234423-95-0

### Drug Class

Breast Feeding

Lactation

Milk, Human

Sodium Hydrogen Exchanger 3 Inhibitor

NHE3 inhibitor